~ Buy the IZERVAY (avacincaptad pegol sodium) Drug Profile, 2024 PDF Report in the Report Store ~

IZERVAY Drug Patent Profile

✉ Email this page to a colleague

Which patents cover Izervay, and what generic alternatives are available?

Izervay is a drug marketed by Astellas and is included in one NDA. There are nine patents protecting this drug.

This drug has one hundred and two patent family members in twenty-seven countries.

The generic ingredient in IZERVAY is avacincaptad pegol sodium. One supplier is listed for this compound. Additional details are available on the avacincaptad pegol sodium profile page.

DrugPatentWatch^® Generic Entry Outlook for Izervay

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be February 14, 2025. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for IZERVAY?
What are the global sales for IZERVAY?
What is Average Wholesale Price for IZERVAY?

Summary for IZERVAY

International Patents:	102
US Patents:	9
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Drug Prices:	Drug price information for IZERVAY
What excipients (inactive ingredients) are in IZERVAY?	IZERVAY excipients list
DailyMed Link:	IZERVAY at DailyMed

Drug patent expirations by year for IZERVAY

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for IZERVAY

Generic Entry Date for IZERVAY^: ⤷ Sign Up* Constraining patent/regulatory exclusivity: ⤷ Sign Up NDA: 217225 Dosage: SOLUTION;INTRAVITREAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for IZERVAY

Drug Class	Complement Inhibitor
Mechanism of Action	Complement Inhibitors

US Patents and Regulatory Information for IZERVAY

IZERVAY is protected by nine US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of IZERVAY is ⤷ Sign Up.

This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting IZERVAY

Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION BY ADMINISTERTING AVACINCAPTAD PEGOL TO THE EYE

Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astellas	IZERVAY	avacincaptad pegol sodium	SOLUTION;INTRAVITREAL	217225-001	Aug 4, 2023		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Astellas	IZERVAY	avacincaptad pegol sodium	SOLUTION;INTRAVITREAL	217225-001	Aug 4, 2023		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up		Y		⤷ Sign Up
Astellas	IZERVAY	avacincaptad pegol sodium	SOLUTION;INTRAVITREAL	217225-001	Aug 4, 2023		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up		Y		⤷ Sign Up
Astellas	IZERVAY	avacincaptad pegol sodium	SOLUTION;INTRAVITREAL	217225-001	Aug 4, 2023		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up		Y		⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

International Patents for IZERVAY

When does loss-of-exclusivity occur for IZERVAY?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 06214437
Patent: Aptamer therapeutics useful in the treatment of complement-related disorders
Estimated Expiration: ⤷ Sign Up

Brazil

Patent: 0607002
Patent: aptámeros terapêuticos úteis no tratamento de desordens relacionadas a complemento
Estimated Expiration: ⤷ Sign Up

Canada

Patent: 97889
Patent: AGENTS THERAPEUTIQUES A BASE D'APTAMERES UTILES DANS LE TRAITEMENT DE TROUBLES LIES AU COMPLEMENT (APTAMER THERAPEUTICS USEFUL IN THE TREATMENT OF COMPLEMENT-RELATED DISORDERS)
Estimated Expiration: ⤷ Sign Up

Patent: 97900
Patent: AGENTS THERAPEUTIQUES A BASE D'APTAMERES UTILES DANS LE TRAITEMENT DE TROUBLES LIES AU COMPLEMENT (APTAMER THERAPEUTICS USEFUL IN THE TREATMENT OF COMPLEMENT-RELATED DISORDERS)
Estimated Expiration: ⤷ Sign Up

Patent: 92874
Patent: AGENTS THERAPEUTIQUES A BASE D'APTAMERES UTILES DANS LE TRAITEMENT DE TROUBLES LIES AU COMPLEMENT (APTAMER THERAPEUTICS USEFUL IN THE TREATMENT OF COMPLEMENT-RELATED DISORDERS)
Estimated Expiration: ⤷ Sign Up

Patent: 24030
Patent: AGENTS THERAPEUTIQUES A BASE D'APTAMERES UTILES DANS LE TRAITEMENT DE TROUBLES LIES AU COMPLEMENT (APTAMER THERAPEUTICS USEFUL IN THE TREATMENT OF COMPLEMENT-RELATED DISORDERS)
Estimated Expiration: ⤷ Sign Up

China

Patent: 1155822
Patent: Aptamer therapeutics useful in the treatment of complement-related disorders
Estimated Expiration: ⤷ Sign Up

Patent: 3352037
Patent: Aptamer therapeutics useful in the treatment of complement-related disorders
Estimated Expiration: ⤷ Sign Up

Patent: 4404046
Patent: Aptamer therapeutics useful in the treatment of complement-related disorders
Estimated Expiration: ⤷ Sign Up

Patent: 8148840
Patent: 用于治疗补体－相关失调的适体治疗 (Aptamer Therapeutics Useful In The Treatment Of Complement-Related Disorders)
Estimated Expiration: ⤷ Sign Up

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering IZERVAY around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
European Patent Office	3019243	PROCÉDÉS POUR TRAITER OU PRÉVENIR DES ÉTATS OPHTALMOLOGIQUES (METHODS FOR TREATING OR PREVENTING OPHTHALMOLOGICAL CONDITIONS)	⤷ Sign Up
Singapore	11201510315T	METHODS FOR TREATING OR PREVENTING OPHTHALMOLOGICAL CONDITIONS	⤷ Sign Up
China	108148840	用于治疗补体－相关失调的适体治疗 (Aptamer Therapeutics Useful In The Treatment Of Complement-Related Disorders)	⤷ Sign Up
Mexico	2016000364	METODOS PARA TRATAR O PREVENIR AFECCIONES OFTALMOLOGICAS. (METHODS FOR TREATING OR PREVENTING OPHTHALMOLOGICAL CONDITIONS.)	⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration